Modern possibilities of pathogenetic therapy of patients with allergic rhinitis
https://doi.org/10.21518/2079-701X-2020-6-101-106
Abstract
The incidence of allergic rhinitis has been increasing rapidly worldwide in recent years. About 40% of the world’s population suffer from allergic inflammation of the nasal mucous membrane. Clinical manifestations of allergic rhinitis are absence or difficulty of nasal breathing, itching, sneezing, nasal congestion and rhinorrhoea, as well as swelling of the face, the presence of dermatitis in the region of the nasal wings, general malaise, smell disturbance. Manifestations of allergies by ENT organs in most cases do not pose a threat to life, but they can cause the development of other pathological processes, bad sleep, irritability, decreased efficiency, mood swings, which, in turn, adversely affects human health and reduces the quality of life. The pathogenesis of allergic rhinitis is based on an immediate hypersensitivity. According to the modern classification, depending on the nature of the course of the disease it is common to identify intermittent and persistent forms.
At present, the drugs of choice in the treatment of patients with allergic rhinitis are intranasal glucocorticosteroids. However, the presence of a concomitant pathology of the nasal cavity in the patient, such as deviated septum, not only significantly impairs the course of nasal inflammatory process, but also creates obstacles to adequate delivery of topical drugs to all parts of the nasal cavity, which, in turn, reduces their effectiveness.
For patients suffering from allergic rhinitis in combination with other pathology of the nasal cavity, combined oral medications may be a good alternative to intranasal sprays. Certain interest for doctors is caused by the appearance of a combined antihistamine drug on the Russian market, which includes a blocker of leukotrienes and H1-histamine receptors of the second generation – montelukast and levocetirizine. The drug can be used both in adults and children from 15 years old for treatment of intermittent and persistent forms of allergic rhinitis.
Timely and properly performed therapy of allergic rhinitis allows to eliminate symptoms of the disease and prevent the development of complications.
About the Authors
V. M. SvistushkinRussian Federation
Valeriy M. Svistushkin, Dr. of Sci. (Med.), professor, Head of the Department of ENT Diseases
8, Bldg. 2, Trubetskaya St., Moscow, 119991
G. N. Nikiforova
Russian Federation
Galina N. Nikiforova, Dr. of Sci. (Med.), professor of the Department of ENT Diseases
8, Bldg. 2, Trubetskaya St., Moscow, 119991
P. S. Artamonova
Russian Federation
Polina S. Artamonova, Postgraduate Student of the Department of Ear, Throat and Nose Diseases of N.V. Sklifosovsky Clinical Medicine Institute
8, Bldg. 2, Trubetskaya St., Moscow, 119991
E. A. Shevchik
Russian Federation
Elena A. Shevchik, Cand. of Sci. (Med), associate professor of the Department of Ear, Throat and Nose Diseases of N.V. Sklifosovsky Clinical Medicine Institute
8, Bldg. 2, Trubetskaya St., Moscow, 119991
References
1. Kryukov A.I., Turovskiy A.B., Bondareva G.P., Semkina O.V. Principles of allergic rhinitis treatment. Meditsinskiy sovet = Medical Council. 2013;(7):42–47. (In Russ.) doi: 10.21518/2079-701X-2013-7-42-47.
2. Kakli H.A., Riley T.D. Allergic rhinitis. Primary Care: Clinics in Office Practice. 2016;43(3):465–475. doi: 10.1016/j.pop.2016.04.009.
3. Vishneva E.A., Namazova-Baranova L.S., Alexeyeva A.A., Ephendiyeva K.E., Levina Y.G., Voznesenskaya N.I. et al. Modern principles of allergic rhinitis therapy in children. Pediatricheskaya farmakologiya = Pediatric pharmacolo gy. 2014;11(1):6–14. (In Russ.) doi: 10.15690/pf.v11i1.889.
4. Zhang Y., Zhang L. Increasing prevalence of allergic rhinitis in China. Allergy, asthma & immunology research. 2019;11(2):156–169. doi: 10.4168/aair.2019.11.2.156.
5. Vandenplas O., Vinnikov D., Blanc P.D., Agache I., Bachert C., Bewick M. et al. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol Pract. 2018;6(4):1274–1286. doi: 10.1016/j.jaip.2017.09.002.
6. Poddighe D., Gelardi M., Licari A., Del Giudice M.M., Marseglia G.L. Nonallergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management. World J Methodol. 2016;6(4):200–213. doi: 10.5662/wjm.v6.i4.200.
7. Brożek J.L., Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines 2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi: 10.1016/j.jaci.2017.03.050.
8. Nikiforova G.N., Svistushkin V.M., Slavsky A.N., Pshonkina D.M. Possibilities of use of the modern antihistamine medecines in therapy of patients with allergic rhinitis. Meditsinskiy sovet = Medical Council. 2017;(8):92–98. (In Russ.) doi: 10.21518/2079-701X-2017-8-92-98.
9. Astaf’eva N., Goryachkina L., Il’ina N., Namazova L., Ogorodova L., Sidorenko I., Smirnova G., Chernyak B. Allergic rhinitis. Pediatricheskaya far makologiya = Pediatric pharmacology. 2008;5(4):81–87. (In Russ.) Available at: https://www.pedpharma.ru/jour/article/view/839.
10. Greiner A.N., Hellings P.W., Rotiroti G., Scadding G.K. Allergic rhinitis. Lancet. 2011;378(9809):2112–2122. doi: 10.1016/S0140-6736(11)60130-X.
11. Gani F., Lombardi C., Bonizzoni G., Rolla G., Brussino L., Landi M. et al. The Characteristics of Severe Chronic Upper-Airway Disease (SCUAD) in Patients with Allergic Rhinitis: A Real-Life Multicenter Cross-Sectional Italian Study. Int Arch Allergy Immunol. 2019;178(4):333–337. doi: 10.1159/000495305.
12. Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A. et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy. 2008;63(Suppl 86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x.
13. Naclerio R.M., Pinto J., deTineo M., Baroody F.M. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc. 2008;29(1):24–28. doi: 10.2500/aap2008.29.3075.
14. Callebaut I., Spielberg L., Hox V., Bobic S., Jorissen M., Stalmans I. et al. Conjunctival effects of a selective nasal pollen provocation. Allergy. 2010;65(9):1173–1181. doi: 10.1111/j.1398-9995.2010.02360.x.
15. van den Oord R.A., Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and metaanalysis. BMJ. 2009;339:b2433. doi: 10.1136/bmj.b2433.
16. Zhu D., Zhu X.W., Jiang X.D., Dong Z. Thymic stromal lymphopoietin expression is increased in nasal epithelial cells of patients with mugwort pollen sensitive-seasonal allergic rhinitis. Chin Med J (Engl). 2009;122(19):2303– 2307. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20079130.
17. Smurthwaite L., Durham S.R. Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep. 2002;2(3):231–238. doi: 10.1007/s11882-002-0024-z.
18. Li H., Sha Q., Zuo K., Jiang H., Cheng L., Shi J., Xu G. Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children. ORL J Otorhinolaryngol Relat Spec. 2009;71(1):50–55. doi: 10.1159/000178165.
19. Roberts G., Xatzipsalti M., Borrego L.M., Custovic A., Halken S., Hellings P.W. et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68(9):1102–1116. doi: 10.1111/all.12235.
20. Calderon M.A., Gerth van Wijk R., Eichler I., Matricardi P.M., Varga E.M., Kopp M.V. et al. European Academy of Allergy and Clinical Immunology. Perspectives on allergen specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol. 2012;23(4):300–306. doi: 10.1111/j.1399-3038.2012.01313.x.
21. Scadding G.K., Durham S.R., Mirakian R., Jones N.S., Leech S.C., Farooque S. et al. British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non allergic rhinitis. Clin Exp Allergy. 2008;38(1):19–42. doi: 10.1111/j.1365-2222.2007.02888.x.
22. Church M.K., Church D.S. Pharmacology of antihistamines Indian J Dermatol. 2013;58(3):219–224. doi: 10.4103/0019-5154.110832.
23. Simons F.E., Simons K.J. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(6):1139–1150.e4. doi: 10.1016/j.jaci.2011.09.005.
24. Ng K.H., Chong D., Wong C.K., Ong H.T., Lee C.Y., Lee B.W., Shek L.P. Central nervous system side effects of first-and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, doubleblind, placebo-controlled comparative study. Pediatrics. 2004;113(2):116– 121. doi: 10.1542/peds.113.2.e116.
25. Di Lorenzo G., Pacor M.L., Pellitteri M.E., Morici G., Di Gregoli A., Lo Bianco C. et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in monotherapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(2):259–267. doi: 10.1111/j.1365-2222.2004.01877.x.
26. Asmanov A.I. The role of surgical methods in the complex treatment of allergic rhinitis in children: dis. – Scientific and Clinical Center of Otorhinolaryngology, Ministry of Health of the Russian Federation, 2012. (In Russ.) Available at: https://elibrary.ru/item.asp?id=19383399.
27. Frank D.O., Kimbell J.S., Cannon D., Pawar S.S., Rhee J.S. Deviated nasal septum hinders intranasal sprays: a computer simulation study. Rhinology. 2012;50(3):311–318. doi: 10.4193/Rhino12.053.
28. Aggarwal R., Cardozo A., Homer J.J. The assessment of topical nasal drug distribution. Clin Otolaryngol Allied Sci. 2004;29(3):201–205. doi: 10.1111/j.1365-2273.2004.00797.x.
29. Benninger M.S., Hadley J.A., Osguthorpe J.D., Marple B.F., Leopold D.A., Derebery M.J., Hannley M. Techniques of intranasal steroid use Otolaryngol Head Neck Surg. 2004;130(1):5–24. doi: 10.1016/j.otohns.2003.10.007.
30. Leonova M.V., Alimova E.E., Dvornikov A.S. Leukotriene receptor antagonists in the treatment of allergic diseases: the review of the effectiveness of montelukast. Pharmateсa = Farmateca. 2017;(s4-17):15–20. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/35333.
31. Li L., Wang R., Cui L., Guan K. Efficacy of montelukast as prophylactic treatment for seasonal allergic rhinitis. Ear Nose Throat J. 2018;97(7):1–16. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30036440.
32. Zharkikh M., Yablonsky S., Mokronosova M. Leukotriens and antileucotriene drugs in allergic rhinitis. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2009;6(5):20–29. (In Russ.) Available at: https://www.pedpharma.ru/jour/article/view/959.
33. Knorr B., Holland S., Rogers .J.D, Nguyen H.H., Reiss T.F. Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections. J Allergy Clin Immunol. 2000;106(3 Suppl):171–178. doi: 10.1067/mai.2000.109424.
34. Shsherbak I.B. Emphasis of antihistamine therapy: levocetirizine. Ukrainskij medicinskij zhurnal = Ukrainian medical journal. 2012;(3):84–85. (In Russ.) Available at: https://www.umj.com.ua/article/35126/akcenty-antigistaminnoj-terapii-levocetirizin.
Review
For citations:
Svistushkin VM, Nikiforova GN, Artamonova PS, Shevchik EA. Modern possibilities of pathogenetic therapy of patients with allergic rhinitis. Meditsinskiy sovet = Medical Council. 2020;(6):101-106. (In Russ.) https://doi.org/10.21518/2079-701X-2020-6-101-106